Kymera Q3 Loss Widens to $132M; KT-579 Phase 1 Achieves ≥90% IRF5 Degradation
KYMR has more than doubled off its 52-week low of $55.66.
Summary
Kymera posted a $132.0M Q3 net loss on sharply higher R&D, but paired it with positive KT-579 Phase 1 data showing ≥90% IRF5 degradation and reaffirmed KT-621 Phase 2b topline data by year-end 2026, backed by $1.6B in cash.
Key Events · Earnings and Guidance · KYMR
-
Q3 Loss Widens on R&D Spend
Net loss was $132.0M ($1.32 per share) versus $82.2M a year ago, as R&D rose to $128.5M from $74.1M and collaboration revenue fell to zero from $2.8M.
-
KT-579 Phase 1 Shows Deep IRF5 Degradation
In healthy volunteers, the trial showed ≥90% median IRF5 degradation across multiple dose levels and 88% TNFα, 94% IL-1β and 98% IFNβ suppression at Day 14, with safety comparable to placebo.
-
Lupus Trial Planned for Early 2027
The LUMORA Phase 1b trial of KT-579 in roughly 30 systemic lupus erythematosus patients is planned to start by early 2027.
-
KT-621 Phase 2b Topline Due Year-End
The last patient completed the week 16 visit in the BROADEN2 Phase 2b atopic dermatitis trial, with topline data expected by year-end 2026 and a first Phase 3 trial planned by mid-2027.
Analysis · KYMR · Life Sciences
The quarter itself is a cost story: R&D jumped to $128.5M from $74.1M a year ago and the net loss widened to $132.0M, with no collaboration revenue booked. More important is the clinical update bundled with it. KT-579 showed deep, sustained IRF5 degradation (≥90% median) and strong suppression of downstream inflammatory cytokines with a placebo-like safety profile, supporting the start of the LUMORA lupus trial by early 2027. The KT-621 atopic dermatitis Phase 2b is fully enrolled and dosed through week 16, with topline data due by year-end 2026—the nearest binary event. With $1.6 billion in cash and runway into 2029, the spending increase is funded and there is no near-term financing need.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KYMR was trading at $122.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.2B. The 52-week trading range was $55.66 to $130.05. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.